Matches in SemOpenAlex for { <https://semopenalex.org/work/W2905229502> ?p ?o ?g. }
- W2905229502 abstract "To study nocturia in patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) after medical or placebo treatment. Patients with LUTS suggestive of BPH from several community clinics were included. Patients completed the International Prostate Symptom Score (I-PSS) questionnaire and a 3-day voiding diary. Urinalysis, prostate-specific antigen (PSA) measurement, and prostate ultrasonography were performed. Nocturnal polyuria (NP) was defined as a nocturnal urine fraction exceeding one third of the daily urine output in elderly men. A total of 148 outpatients were randomized to drug treatment (tamsulosin) or placebo treatment. After 8 weeks of treatment, they were re-evaluated using a 3-day voiding diary, PSA measurement, prostate volume (PV), I-PSS, etc. The average I-PSS score was 20.3, storage symptom score was 11.7, voiding symptom score was 8.6, quality of life (QoL) score was 3.7, PV was 40.4 ± 19.4 ml, and nocturnal urine volume (NUV) was 845.7 ± 339.0 ml. The mean frequency of nocturia was 2.3 ± 1.1 per day, and 94% of the patients had a nocturia frequency of more than two times per day. Of these patients, 76.5% had NP. A significant correlation was found between NUV and the amount of water intake at night and 4 h before sleep (r = 0.419,P = 0.002; r = 0.302,P = 0.031). Eighty patients were randomized to drug treatment (tamsulosin) and 68 patients were randomized to placebo treatment. The I-PSS score was 16.8 ± 4.9 to 19.3 ± 5.0 (p = 0.002), the storage symptom score was 10.3 ± 3.4 to 10.7 ± 3.4 (p = 0.007), and the voiding symptom score was 7.5 ± 2.4 to 8.6 ± 2.3 (p = 0.003). The frequency of daytime urination was 7.5 ± 2.6 to 8.1 ± 2.6 (p = 0.002), maximum urine volume (ml) was 372.8 ± 103.3 to 302.8 ± 119.3 (p = 0.007), and morning urine volume (ml) was 280.5 ± 111.7 to 259.5 ± 100.7 (p = 0.003). However, the frequency of nocturia score was 2.8 ± 0.7 to 3.0 ± 0.6 (p = 0.306) and the nocturnal urine volume (ml) was 800.7 ± 323.0 to 845.7 ± 303.5 (p = 0.056), which did not change significantly. There were significant differences between the NP and non-NP groups in the duration of LUTS, first voided urine volume, daytime urination frequency, and the amount of water intake at night and 4 h before sleep. Among the symptoms of LUTS, the improvement rates for nocturia were the lowest after medical treatment for BPH. The α-blockers did not improve nocturia, which was a common symptom accompanying LUTS suggestive of BPH. Our results showed that the prevalence of NP was 76.5% and that NP was significantly related to the amount of water intake during the evening and before sleep. ISRCTN registry, Trial registration number (TRN): ISRCTN85509614 , Date of registration: 30/10/2018. This trial was registered retrospectively." @default.
- W2905229502 created "2018-12-22" @default.
- W2905229502 creator A5051233887 @default.
- W2905229502 creator A5066296867 @default.
- W2905229502 creator A5079974007 @default.
- W2905229502 creator A5081068772 @default.
- W2905229502 creator A5081276325 @default.
- W2905229502 date "2018-12-01" @default.
- W2905229502 modified "2023-10-01" @default.
- W2905229502 title "The evaluation of nocturia in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and the analysis of the curative effect after medical or placebo therapy for nocturia: a randomized placebo-controlled study" @default.
- W2905229502 cites W1500472837 @default.
- W2905229502 cites W1965649799 @default.
- W2905229502 cites W1990276574 @default.
- W2905229502 cites W1995241520 @default.
- W2905229502 cites W2008739655 @default.
- W2905229502 cites W2013795777 @default.
- W2905229502 cites W2015519667 @default.
- W2905229502 cites W2026111694 @default.
- W2905229502 cites W2038092217 @default.
- W2905229502 cites W2042875995 @default.
- W2905229502 cites W2043796059 @default.
- W2905229502 cites W2045646618 @default.
- W2905229502 cites W2048007562 @default.
- W2905229502 cites W2051039299 @default.
- W2905229502 cites W2066869960 @default.
- W2905229502 cites W2094259156 @default.
- W2905229502 cites W2098019892 @default.
- W2905229502 cites W2100358327 @default.
- W2905229502 cites W2110403967 @default.
- W2905229502 cites W2128138585 @default.
- W2905229502 cites W2134226400 @default.
- W2905229502 cites W2154119935 @default.
- W2905229502 cites W2166258946 @default.
- W2905229502 cites W2993539218 @default.
- W2905229502 cites W4234671625 @default.
- W2905229502 cites W4253207321 @default.
- W2905229502 doi "https://doi.org/10.1186/s12894-018-0426-4" @default.
- W2905229502 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6293598" @default.
- W2905229502 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30545338" @default.
- W2905229502 hasPublicationYear "2018" @default.
- W2905229502 type Work @default.
- W2905229502 sameAs 2905229502 @default.
- W2905229502 citedByCount "7" @default.
- W2905229502 countsByYear W29052295022019 @default.
- W2905229502 countsByYear W29052295022020 @default.
- W2905229502 countsByYear W29052295022021 @default.
- W2905229502 countsByYear W29052295022022 @default.
- W2905229502 countsByYear W29052295022023 @default.
- W2905229502 crossrefType "journal-article" @default.
- W2905229502 hasAuthorship W2905229502A5051233887 @default.
- W2905229502 hasAuthorship W2905229502A5066296867 @default.
- W2905229502 hasAuthorship W2905229502A5079974007 @default.
- W2905229502 hasAuthorship W2905229502A5081068772 @default.
- W2905229502 hasAuthorship W2905229502A5081276325 @default.
- W2905229502 hasBestOaLocation W29052295021 @default.
- W2905229502 hasConcept C121608353 @default.
- W2905229502 hasConcept C126322002 @default.
- W2905229502 hasConcept C126894567 @default.
- W2905229502 hasConcept C142724271 @default.
- W2905229502 hasConcept C159110408 @default.
- W2905229502 hasConcept C168563851 @default.
- W2905229502 hasConcept C204787440 @default.
- W2905229502 hasConcept C27081682 @default.
- W2905229502 hasConcept C2776235491 @default.
- W2905229502 hasConcept C2776547966 @default.
- W2905229502 hasConcept C2777333188 @default.
- W2905229502 hasConcept C2777562237 @default.
- W2905229502 hasConcept C2779225474 @default.
- W2905229502 hasConcept C2779478474 @default.
- W2905229502 hasConcept C2779951463 @default.
- W2905229502 hasConcept C2780002838 @default.
- W2905229502 hasConcept C2780542891 @default.
- W2905229502 hasConcept C71924100 @default.
- W2905229502 hasConcept C77411442 @default.
- W2905229502 hasConceptScore W2905229502C121608353 @default.
- W2905229502 hasConceptScore W2905229502C126322002 @default.
- W2905229502 hasConceptScore W2905229502C126894567 @default.
- W2905229502 hasConceptScore W2905229502C142724271 @default.
- W2905229502 hasConceptScore W2905229502C159110408 @default.
- W2905229502 hasConceptScore W2905229502C168563851 @default.
- W2905229502 hasConceptScore W2905229502C204787440 @default.
- W2905229502 hasConceptScore W2905229502C27081682 @default.
- W2905229502 hasConceptScore W2905229502C2776235491 @default.
- W2905229502 hasConceptScore W2905229502C2776547966 @default.
- W2905229502 hasConceptScore W2905229502C2777333188 @default.
- W2905229502 hasConceptScore W2905229502C2777562237 @default.
- W2905229502 hasConceptScore W2905229502C2779225474 @default.
- W2905229502 hasConceptScore W2905229502C2779478474 @default.
- W2905229502 hasConceptScore W2905229502C2779951463 @default.
- W2905229502 hasConceptScore W2905229502C2780002838 @default.
- W2905229502 hasConceptScore W2905229502C2780542891 @default.
- W2905229502 hasConceptScore W2905229502C71924100 @default.
- W2905229502 hasConceptScore W2905229502C77411442 @default.
- W2905229502 hasIssue "1" @default.
- W2905229502 hasLocation W29052295021 @default.
- W2905229502 hasLocation W29052295022 @default.
- W2905229502 hasLocation W29052295023 @default.
- W2905229502 hasLocation W29052295024 @default.
- W2905229502 hasOpenAccess W2905229502 @default.
- W2905229502 hasPrimaryLocation W29052295021 @default.